Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOTHOT: Dupilumab in At-risk Type-2 Inflammatory Asthma
NCT07309614Phase 3Recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of dupilumab in asthma, sponsored by Université de Sherbrooke. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07309614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309614.